Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an update.
Race Oncology Limited announced the approval of its replacement Constitution by shareholders during its Annual General Meeting. This move signifies a strategic step in the company’s governance, potentially impacting its operational framework and stakeholder relations. The adoption of the new Constitution may align with Race Oncology’s broader goals of advancing its clinical programs and exploring strategic partnerships.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is an ASX-listed Phase 3 clinical biopharmaceutical company focused on cancer care. Its primary product, RCDS1 (E,E-bisantrene), is an anticancer agent targeting G4-DNA & RNA binding, inhibiting the cancer growth regulator MYC. The company is advancing RCDS1’s proprietary formulation, RC220, for multiple oncology indications, including acute myeloid leukemia and non-small cell lung cancer. Race Oncology collaborates with various institutions and is exploring partnerships to enhance global access to RC220.
Average Trading Volume: 546,429
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.5M
For a thorough assessment of RAC stock, go to TipRanks’ Stock Analysis page.